Maxime Verhoeven

90 Chapter 5 10. Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at one year - the lithe study. Arthritis Rheum. 63 , 609–621 (2011). 11. van Nies, J. A. B., Tsonaka, R., Fautrel, B. & van Mil-van der Helm, A. H. M. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist ? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann. Rheum. Dis. 74 , 806–812 (2015). 12. Stack, R. J. et al. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. Ann. Rheum. Dis. 71 , 493–497 (2012). 13. Buckley, F., Finckh, A., Huizinga, T. W. J., Dejonckheere, F. & Jansen, J. P. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J. Manag. care Spec. Pharm. 21 , 409–423 (2015). 14. van der Heijde, D. Erosions versus joint space narrowing in rheumatoid arthritis: what do we know? Ann. Rheum. Dis. 70 , 116–118 (2011). 15. Bruynesteyn, K. et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J. Rheumatol. 29 , 2306–2312 (2002).